Trial | NCT00278824  Report issue

Title

Fentanyl Transdermal Patch With CHADD™ for Breakthrough Pain in Patients With Moderate to Severe Non-Malignant Pain
A Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy of CHADD™ Applied Over a Transdermal Fentanyl Patch for the Treatment of Breakthrough Pain in Patients With Moderate to Severe Non-malignant Chronic Pain

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Terminated

  • Indication/Condition

    Pain

  • Intervention/Treatment

    fentanyl ...

  • Study Participants

    109
A multi-center study to evaluate the efficacy of CHADD (Controlled Heat-Assisted Drug Delivery) applied over a 50 mcg/hr ZR-02-01 matrix transdermal fentanyl patch for the treatment of breakthrough pain in adult patients with moderate to severe non-malignant chronic pain. The open-label study arm will last up to 12 days. The double-blind arm will last up to 15 days. Eligible patients who complete the open-label arm will be allowed to enroll in the double-blind study arm.
ZARS Pharma is developing a Matrix Transdermal Fentanyl/CHADD (Controlled Heat-Assisted Drug Delivery) Drug Delivery System to be used for the treatment of chronic and breakthrough pain. The Matrix Transdermal Fentanyl/CHADD Drug Delivery System has been designed to provide long-term delivery of fentanyl for the treatment of chronic pain as well as intermittent increases in fentanyl concentrations for the treatment of breakthrough pain. Breakthrough pain is defined as a transitory exacerbation of pain that occurs on a background of otherwise stable pain in a patient receiving chronic opioid therapy.

Matrix Transdermal Fentanyl/CHADD Drug Delivery System has 2 components: a matrix transdermal fentanyl patch (the ZR-02-01 patch in doses of 25, 50, 75 and 100 mcg/hr) with corresponding thin film dressing (ie, overlay) and the CHADD (Controlled Heat-Assisted Drug Delivery).

The matrix transdermal fentanyl patch provides a continuous delivery of fentanyl over 72 hours, in a manner similar to Duragesic®. During a breakthrough pain episode, a CHADD unit is placed over (adhered to) the matrix transdermal fentanyl patch. The CHADD is a thin patch-like chemical heating device that generates a controlled level of heat for approximately 15-20 minutes. The application of heat delivers increased amounts of fentanyl when applied over the ZR-02-01 matrix transdermal fentanyl patch.
Study Started
Jan 31
2006
Primary Completion
Aug 31
2006
Study Completion
Aug 31
2006
Last Update
Jun 05
2012
Estimate

Drug Matrix Transdermal Fentanyl/CHADD Drug Delivery System

Patch applied every 3 days for 15 days

  • Other names: ZR-02-01, Fentanyl Transdermal Matrix Patch

Drug Placebo Patch

Placebo patch applied every 3 days for 15 days

  • Other names: Placebo Matrix Patch

50 mcg/hr matrix fentanyl patch Experimental

active 50 mcg/hr ZR-02-01 matrix transdermal fentanyl patch (20 cm2)

Placebo Patch Placebo Comparator

placebo (20 cm2) will be indistinguishable in size, shape, and appearance to the active matrix fentanyl patch

Criteria 

Inclusion Criteria:

Patient is 18 through 70 years of age.
Patient has moderate to severe non-malignant chronic pain.
Patient is opioid-tolerant, requires treatment with chronic opioids and is currently taking a dose of 50 mcg/hr transdermal fentanyl for the treatment of chronic pain. Patient must have been taking this dose for at least 2 weeks.
Patient must be experiencing 1 to 4 episodes of target breakthrough pain (breakthrough pain that is related to the patient's chronic pain condition) a day while taking a dose of 50 mcg/hr transdermal fentanyl.

Exclusion Criteria:

Patient has active cancer.
Patient has a history of substance abuse or has a substance abuse disorder.
Patient is pregnant or breastfeeding.
No Results Posted